VJOncology is committed to improving our service to you

ASCO 2020 | FIH study of CX-2029 in patients with advanced cancer

VJOncology is committed to improving our service to you

Melissa Johnson

Melissa Johnson, MD, Sarah Cannon Research Institute, Nashville, TN, highlights results from the PROCLAIM-CX-2029 study (NCT03543813). This first in human study evaluated CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor) in patients with advanced cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter